Cannabis vaporizer company Pax Labs raises benchmark $420 million in funding

pax marijuana funding, Cannabis vaporizer company Pax Labs raises benchmark $420 million in funding

Pax Labs, a San Francisco-based maker of vaporizers, confirmed it raised $420 million in equity financing, a record for a U.S.-based marijuana company.

The firm said the round included both new and existing institutional investors, including New York-based Tiger Global Management and San Francisco-based Tao Capital Partners.

Pax’s raise nearly doubled the previous high for a U.S. cannabis company, a $250 million debt financing by California-based multistate marijuana operator MedMen in March.

“This financing round allows us to invest in new products and new markets, including international growth in markets like Canada and exploring opportunities in hemp-based CBD extracts,” Pax CEO Bharat Vasan said in a news release.

According to technology publication The Information, Pax initially sought to raise about $150 million, but surging interest from investors boosted that figure.

The investment represents increasing mainstream interest in the cannabis space.

“It is a further signal that the floodgates are starting to open given that institutional investors have invested,” Matt Karnes, founder and managing partner of New York-based GreenWave Advisors, told Marijuana Business Daily.

Cowen, a New York investment management company, likely was involved in Pax’s financing, sources told MJBizDaily. Cowen declined to comment.

Pax, which spun off from e-cigarette producer Juul in 2017, was founded in 2007.

In late 2018, the company closed a $20 million funding round, opting to keep the investment small to “avoid becoming overly dependent on venture capital,” according to Vasan.

Get access to more in-depth market analysis, premium features on cannabis investing trends and monthly executive webcasts with an Investor Intelligence subscription.

Latest Headlines

2 comments on “Cannabis vaporizer company Pax Labs raises benchmark $420 million in funding
  1. vonGunten on

    Cannabis plante ancestrale,et un plaisirs d avoir du produit de bonne qualitée tout en restant le plus naturellement cultivé,pour les malades que cette plante soulage Pour moi que du positif dans une consomation adaptée selon les cas,et une opportunitée que l on puisse tous faire la culture pour nôtre prôpre consommation ou des produits sertifiés sans ajouts ni pessticide…Legalise Cannabis…

  2. Richard Cleary on

    Please somebody let me know the TICKER symbol for the company that deal’s with MULTIPLE SCLEROSIS, amoung others, i’d like to invest.

Leave a Reply

Your email address will not be published. Required fields are marked *